Shalyn Fullerton

Shalyn Fullerton

Auto-generated profile, based on publicly available information

Shalyn Fullerton

Mayo Clinic

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2025 in The American Surgeon™
Verified
Journal Article
Closed access
STSibi Krishna Thiyagarajan
Sibi Krishna Thiyagarajan
SFShalyn Fullerton
Shalyn Fullerton
Alfredo VerasteguiAlfredo Verastegui
Alfredo Verastegui
KPKatherine Poruk
Katherine Poruk
JSJohn A. Stauffer
John A. Stauffer
Background: Whistal (Whipple + Distal) is a rare parenchyma-preserving technique for select patients with disease in both the pancreatic head and tail, sparing a disease-free middle segment. It may also be used after prior partial pancreatectomy. Surgical resection remains the cornerstone of treatment for pancreatic diseases such as PDAC, RCC metastasis, and multifocal IPMN. Whistal may balance oncologic control with pancreatic function preservation. Though infrequent, it is practiced and reported in literature. Methods: With IRB approval, a retrospective review of a prospective database (Aug 1999-Mar 2024) identified Whistal cases, categorized as staged Whistal (SW) or concomitant whistal (CW). Perioperative outcomes were assessed via Clavien-Dindo and ISGPS. A PubMed search identified reported middle segment pancreatectomy (Whistal) cases. Results: Of 2008 resections (Aug 1999-Mar 2024), 5 were Whistals (3 CW, 2 SW) for PDAC (n = 3), RCC (n = 1), IPMN (n = 1), and bile duct stricture (n = 1). Rates for major morbidity, POPF, and DGE were each 40%. Literature review found 26 papers reporting 52 additional Whistal cases. Conclusion: Whistal is safe for select patients, but wider adoption and long-term data are needed to confirm its efficacy.